BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair SEC-Qualified Financial Expert and Life Sciences Veteran Brings 29 Years of Accounting Leadership to the BoardPompano Beach, Fla, March 23, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the appointment of J ...

Core Viewpoint - BioStem Technologies, Inc. will release its fourth quarter and full year 2025 financial results on March 24, 2026, and will host a conference call and webcast at 4:30 PM ET [1]. Group 1: Company Overview - BioStem Technologies is a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products for regenerative medicine [1][3]. - The company utilizes a proprietary BioRetain processing method, which is designed to maintain growth factors and preserve tissue structure [3]. - BioStem's quality management system has been accredited by the American Association of Tissue Banks and complies with current Good Tissue Practices and Good Manufacturing Processes [3]. Group 2: Upcoming Events - The upcoming conference call and webcast will feature an overview of the quarter presented by CEO Jason Matuszewski and CFO Brandon Poe [2]. - Registration for the event is available through a provided link [2]. Group 3: Contact Information - For further inquiries, BioStem can be contacted via their website, email, or social media platforms [5].

Core Insights - BioStem Technologies, Inc. will present at the 46th Annual TD Cowen Healthcare Conference in Boston, MA, highlighting its focus on perinatal tissue-derived products for advanced wound care [1]. Company Overview - BioStem Technologies is a leading innovator in the MedTech sector, specializing in the development, manufacturing, and commercialization of allografts for regenerative therapies derived from perinatal tissue [3]. - The company utilizes its proprietary BioRetain® processing method, which is designed to maintain growth factors and preserve tissue structure, leveraging the latest research in regenerative medicine [3]. - BioStem's quality management system and standard operating procedures are accredited by the American Association of Tissue Banks (AATB) and comply with current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP) [3]. - The company's product portfolio includes brands such as VENDAJE®, VENDAJE AC®, American Amnion™, American Amnion AC™, and Neox® and Clarix® product lines [3].

Core Insights - BioStem Technologies has acquired the surgical and wound care business of BioTissue Holdings for approximately $15 million, with potential additional payments based on regulatory milestones and royalties [7][8] - This acquisition significantly enhances BioStem's commercial capabilities and expands its product offerings in the acute wound care market [5][6] Group 1: Acquisition Details - The acquisition includes BioTissue's Neox® and Clarix® product lines, along with its commercial infrastructure, which consists of a nationwide sales network and key GPO contracts [4][5] - BioTissue's surgical and wound care business generated approximately $29 million in sales in 2025 and is expected to contribute positively to BioStem's EBITDA in 2026 [8] Group 2: Strategic Implications - The acquisition allows BioStem to diversify into new markets, particularly in acute wound care and soft-tissue repair, thereby broadening its existing product lines [5][6] - Barry Hassett has been promoted to Chief Commercial Officer to lead the integrated commercial team, leveraging his extensive experience in the industry [9] Group 3: Financial Overview - The upfront cash payment for the acquisition is approximately $15 million, with potential additional payments of up to $25 million based on regulatory and commercial milestones [7] - Post-acquisition, BioStem's cash and restricted cash balance is approximately $16 million [8]